Abstract
The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Current Pharmaceutical Design
Title:Natural Products as Promising Therapeutics for Treatment of Influenza Disease
Volume: 21 Issue: 38
Author(s): Milan Sencanski, Draginja Radosevic, Vladimir Perovic, Branislava Gemovic, Maja Stanojevic, Nevena Veljkovic and Sanja Glisic
Affiliation:
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Abstract: The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Export Options
About this article
Cite this article as:
Sencanski Milan, Radosevic Draginja, Perovic Vladimir, Gemovic Branislava, Stanojevic Maja, Veljkovic Nevena and Glisic Sanja, Natural Products as Promising Therapeutics for Treatment of Influenza Disease, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002113426
DOI https://dx.doi.org/10.2174/1381612821666151002113426 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of the Interaction between HIV-1 Integrase and its Cofactor LEDGF/p75: A Promising Approach in Anti-Retroviral Therapy
Mini-Reviews in Medicinal Chemistry Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews Prediction of the Functional Roles of Small Molecules in Lipid Metabolism Based on Ensemble Learning
Protein & Peptide Letters Anti-Mycobacterial Activity of Quinolones. Triazoloquinolones a New Class of Potent Anti-Mycobacterial Agents
Anti-Infective Agents in Medicinal Chemistry Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Quantum Mechanical Methods for Drug Design
Current Topics in Medicinal Chemistry The Family is Growing: Old and New Members of the Family of Site- Specific Recombinases and Their Application to Genome Engineering
Current Pharmacogenomics Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drug Repurposing: An Alternative Strategy to Treat COVID-19
Current Pharmaceutical Biotechnology Medicinal Chemistry of Paclitaxel and its Analogues
Current Medicinal Chemistry Synthesis of Specific Protein Phosphatase Inhibitors, Tautomycin and Tautomycetin toward Structure-Activity Relationship Study
Current Medicinal Chemistry Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
Current Reviews in Clinical and Experimental Pharmacology Quality of Experience: A New Paradigm for Resource Management in Wireless Multimedia Networks
Recent Patents on Computer Science Materials Degradation in PVC Medical Devices, DEHP Leaching and Neonatal Outcomes
Current Medicinal Chemistry Antiviral Strategies: The Present and Beyond
Current Molecular Pharmacology γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Deep Sequencing Approaches to Antibody Discovery
Current Drug Discovery Technologies Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Assessment of Chemicals Applying Partial Order Ranking Techniques
Combinatorial Chemistry & High Throughput Screening Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design